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ABSTRACT: Electrospinning is increasingly becoming a viable means
of producing drug delivery vehicles for oral delivery, particularly as issues
of manufacturing scalability are being addressed. In this study,
electrospinning is explored as a taste-masking manufacturing technology
for bitter drugs. The taste-masking polymer Eudragit E PO (E-EPO) was
electrospun, guided by a quality by design approach. Using a design of
experiment, factors inﬂuencing the production of smooth ﬁbers were
investigated. Polymer concentration, solvent composition, applied
voltage, ﬂow rate, and gap distance were the parameters examined. Of
these, polymer concentration was shown to be the only statistically
signiﬁcant factor within the ranges studied (p-value = 0.0042). As the
concentration increased, smoother ﬁbers were formed, coupled with an
increase in ﬁber diameter. E-EPO (35% w/v) was identiﬁed as the optimum concentration for smooth ﬁber production. The
optimized processing conditions identiﬁed were a gap distance of 175 mm, an applied voltage of between 15 and 20 kV, and a
ﬂow rate of 1 mL/h. Using this knowledge, the production optimization of electrospun E-EPO with chlorpheniramine maleate
(CPM), a bitter antihistamine drug, was explored. The addition of CPM in drug loads of 1:6 up to 1:10 CPM/E-EPO yielded
smooth ﬁbers that were electrospun under conditions similar to placebo ﬁbers. Solid-state characterization showed CPM to be
molecularly dispersed in E-EPO. An electronic tasting system, or E-tongue, indicated good taste-masking performance as
compared to the equivalent physical mixtures. This study therefore describes a means of producing, optimizing, and assessing
the performance of electrospun taste-masked ﬁbers as a novel approach to the formulation of CPM and potentially other bitter
drug substances.
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1. INTRODUCTION
Electrospinning is based on the ultrafast removal of solvents
from a ﬂuid mixture to form solid micro- and nanoﬁbers.1 The
method utilizes a high-voltage electric ﬁeld to form a continuous
jet of liquid that subsequently dries and deposits on a collector
plate as the ﬁbrous material. The applications of this technology
include ﬁltration, production of protective clothing, tissue
engineering, and more recently drug delivery.2 In the
therapeutics arena, electrospun ﬁbers are promising candidates
for drug delivery owing to their high surface area to volume ratio
for release, their structural ﬂexibility, and their ability to
encapsulate high drug loadings in polymeric matrices, the
polymers allowing a range of performance functions in the
body.3 One such recent application of electrospinning is as an
approach to taste-masking for bitter drugs.3−7 Poor palatability
of medicines is one of the main compliance barriers within the
pediatric population, making most liquids unsuitable, and yet
large coated solid dosage forms cannot be swallowed by
children. By using taste-masking polymers, bitter drugs can be
encapsulated in a form that can be both palatable and easy to
swallow. Electrospun ﬁbers can then be formulated into age
appropriate dosage forms such as oral ﬁlms or mini-tablets.3,6,8
While systems such as microspheres have been extensively
studied, the use of nanoﬁbers is a relatively new approach and
little is known with regard to production optimization,
particularly concerning the eﬀects of drug addition on ﬁber
characteristics and the associated taste-masking performance.
To develop electrospinning within the pharmaceutical ﬁeld, it
is necessary to thoroughly explore the spinning properties of
polymers relevant to therapeutic use while also being mindful of
the need for therapeutic, as well as production, performance.
Relatively recently, the understanding of scalability of electro-
spinning has increased very considerably, thus opening up the
potential for viable oral delivery, which requires high volume
manufacture.9 However, by the same token, the use of materials
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typically associated with oral delivery have not yet been
extensively studied as electrospinning materials. The challenge
therefore lies in the need to consider:
(a) Spinnability of pharmaceutical grade materials for which
there is little or no precedent
(b) Formation optimization for those materials, particularly
being mindful of the need to consider the eﬀects of drug
addition
(c) Development of suitable markers that allow reasonable
prediction of biological performance at a preclinical stage.
In this study, we explore the production of Eudragit E PO (E-
EPO) ﬁbers, a taste-masking polymer, both alone and
incorporating chlorpheniramine maleate (CPM), an antihist-
amine used by children for conditions such as urticaria, hay
fever, and relief of itching associated with chicken pox and is also
known to have a bitter taste.10 E-EPO is a pH-sensitive polymer
that masks the bitter taste of CPM by physically encapsulating
the drug and only releasing it at pH < 5.11 This means CPM
would not be released in mouth saliva, which has a pH of
approximately 7.4.12 In particular, we study in detail the
production of the loaded and unloaded ﬁbers so as to provide a
guide for others intending to use this polymer in nanoﬁber
formulations and also to provide insights into the potential
eﬀects of drug addition on spinning parameter optimization. In
addition, we investigate the taste of the ﬁbers using a biosensor
approach so as to allow early screening and product optimization
to facilitate the design of the ﬁnal dosage form.
Electrospinning production is inﬂuenced by a number of
parameters that can be generally classiﬁed as solution, process,
and environmental factors which have been widely studied for
small-scale production.13 Desired characteristics of a ﬁber can
range from morphological to pharmaceutical activity consid-
erations, while the range of manufacturing parameters, and the
possibility of their interaction on inﬂuence, render a single
parameter approach inappropriate and necessitate multifactorial
methodologies in order to identify key production character-
istics.
For pharmaceuticals, a systematic understanding of parameter
inﬂuence is extremely helpful. Although there are several studies
that have involved factorial or design of experiment (DoE)
approaches,14−23 for electrospinning there is a particular need
for pharmaceuticals for information pertinent to quality by
design (QbD) approaches; these allow for the quality of an end
product to be built in by design, rather than reaching these
attributes empirically. This is in line with the recommendations
given by the ICHQ8 pharmaceutical development guidelines.24
The DoE in this study was used to screen for the most
inﬂuential factors in producing smooth E-EPO nanoﬁbers.
Smooth ﬁbers were deﬁned as ﬁbers with no bead-on-strings and
those that have the most uniform ﬁber diameter distribution.
The factors chosen to be controlled represent the critical
material attributes (CMAs) and were polymer concentration
and solvent mixture. The critical process parameters (CPPs)
explored were ﬂow rate, applied voltage, and gap distance. The
output criteria of smooth ﬁbers represent the critical quality
attributes (CQAs) of the ﬁbers formed. Figure 1 shows a
summary of the DoE design space. Once E-EPO ﬁbers were
electrospun with and without the drug, taste-masking assess-
ment of CPM-loaded ﬁbers was performed.
The electronic tasting system, or E-tongue, uses potentio-
metric measurement principles to assess the taste of a substance
as compared to a reference material.25 Thus, the taste-masking
eﬃciency of electrospun CPM ﬁbers was assessed compared to
that of placebo ﬁbers and physical mixtures in order to establish
that the optimized ﬁbers had the potential for eﬀective taste-
masking. To our knowledge, this is the ﬁrst study to use an e-
tongue for taste assessment of electrospun nanoﬁbers. In this
manner, it is intended that the study may provide a blueprint for
the design and characterization of taste-masked electrospun
ﬁbers, the approach being designed with a view to both
pharmaceutical production requirements and therapeutic
acceptability.
2. EXPERIMENTAL SECTION
2.1. Electrospinning. 2.1.1. Preparation of Precursor
Solutions. E-EPO, described as basic butylated methacrylate
copolymer in the European Pharmacopoeia, is a white powder
with an average molar mass of approximately 47 000 g/mol;26
the polymer was kindly donated by Evonik (Darmstadt,
Germany). E-EPO solutions were prepared by dissolving 15−
50% w/v E-EPO in absolute ethanol or ethanol in combination
with water. The mixture was then magnetically stirred at a
temperature of 40 °C for 2−3 h. The solution was allowed to rest
for a day at ambient conditions before electrospinning. Drug-
loaded E-EPO solutions were prepared by adding CPM directly
to the polymer solution in drug to polymer ratios of 1:2 to 1:10.
CPM was purchased from Cambridge Bioscience (Cambridge,
UK).
2.1.2. Manufacturing. A Spraybase electrospinning instru-
ment (Spraybase, Dublin, Ireland) was used to manufacture the
ﬁbers. In the electrospinning process, the prepared solution was
drawn in a 5 mL Terumo syringe (Surrey, UK), attached to a
syringe pump. The syringe was connected to a stainless steel
needle, with a diameter of 0.7 mm, via a connector tube. The
viscous solution was fed through the needle at ﬂow rates
between 0.5 and 2 mL/h. Applied voltages up to 25 kV were
applied to the polymer solutions, evaporating the solvent,
allowing the solid ﬁbers to deposit on a grounded metal plate
collector (14.5 × 23 cm). The collector was covered in
aluminum foil for ease of ﬁber removal. The gap distance
between the needle and the collector plate was set between 150
and 200 mm. Room temperature (°C) and relative humidity
(RH) (%) readings were recorded. The temperature ranged
between 19 and 28 °C, and the RH ranged between 27 and 45%.
Figure 1. DoE design space, with CQAs in the inner circle and CPPs/
CMAs in the peripheral circles.
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2.2. Viscosity. Viscosity measurements of E-EPO at
increasing concentrations were taken to determine the chain
entanglement concentration. The viscosity of samples was
measured using a Bohlin Gemini HR nano dynamic rheometer
at a shear stress of 1−30 Pa. Instantaneous viscosity values
quoted are those recorded at a shear stress of approximately 5
Pa.
2.3. Conductivity and pH. The conductivity and pH of
samples were measured using a SciQuip 902 conductivity meter.
The probes were calibrated using reference solutions as per the
manufacturer’s instructions.
2.4. Experimental Design. ADoE approach was utilized to
optimize the electrospinning of E-EPO on its own using a
deﬁnitive screening design. Deﬁnitive screening designs help to
detect the main eﬀects of input parameters on a particular
outcome in the most eﬃcient way possible.27 JMP Pro 12.0.1
(SAS Institute) was used for experimental design, predictive
modeling, and data analysis. Smooth nonbeaded ﬁbers, with a
reduced ﬁber diameter, were set as the desired output criteria.
Five factors were investigated at three levels of each, as shown in
Table 1. The experiments were performed over two diﬀerent
days or blocks. The sequence in which these runs were carried
out was randomized to reduce variability. The data were ﬁtted to
a standard least squares model, yielding linear regression and
analysis of variance (ANOVA) results.
2.5. Scanning Electron Microscopy (SEM). A sample of
the ﬁber collected was adhered onto aluminum scanning
electron microscopy (SEM) stubs (TAAB Laboratories, UK)
using a carbon-coated double-sided tape. To render them
conductive, a thin coating of gold was applied in a Quorum
Q150T sputter coater (Quorum Technologies Ltd. East Sussex,
UK) in an argon atmosphere. A scanning electron microscope
FEI Quanta 200 FEG (FEI, USA) was used to image the ﬁber
morphology. ImageJ 1.46R software (NIH,Maryland, USA) was
used to measure the diameters of the ﬁbers imaged. OriginPro
9.4 (Origin Lab, Massachusetts, USA) was used to construct the
histograms of ﬁber diameter distributions.
2.6. Thermogravimetric Analysis (TGA). Thermogravi-
metric analysis (TGA) of pure drug, polymer, physical mixtures,
placebo ﬁber, and drug-loaded ﬁbers was carried out using a TA
Instruments Hi-Res 2950 thermogravimetric analyzer (TA
Instruments, New Castle, Delaware, USA). A purge nitrogen
gas ﬂow rate of 60 mL/min was used for the furnace and 40 mL/
min for the TGA head. Samples (mass 5−15 mg) were analyzed
in open aluminum PerkinElmer pans with a heating rate of 10
°C/min from 30 to 500 °C. Data analysis was carried out with
TA Universal Analysis software, version 4.5A.
2.7. Diﬀerential Scanning Calorimetry (DSC). Modu-
lated temperature diﬀerential scanning calorimetry (MTDSC)
thermograms of pure drug, polymer, physical mixture, and
electrospun ﬁbers were recorded using a TA Instruments Q2000
calorimeter (TA Instruments, New Castle, Delaware, USA).
Sample weights ranged from 4 to 8 mg and were sealed in a 40
μL aluminum PerkinElmer standard pan. A pinhole was
manually formed in the lids to allow for solvent evaporation.
Samples were heated under nitrogen gas (ﬂow rate 50 mL/min)
at a heating rate of 2 °C/min ramped up to 150 °C, amplitude
±0.212 °C, and a period of 40 s. Data analysis was carried out
with TA Universal Analysis software, version 4.5A.
2.8. Powder X-ray Diﬀraction (XRD). Solid state
characterization of CPM and E-EPO before and after electro-
spinning was completed using a Rigaku MiniFlex 600 X-ray
diﬀractometer (Rigaku, Tokyo, Japan). Cu Kα radiation was
operated at 40 mV and 15 mA. Patterns were recorded over the
2θ range 3°−40° at a scan rate of 3 or 5°/min, with an interval of
0.02° or 0.005°, respectively. RAW ﬁles produced were
converted to X-ray diﬀraction (XRD) data ﬁles using PowDLL
version 2.51 ﬁle converter software. The data were then viewed
on X’Pert Data Viewer version 1.2F.
2.9. Fourier Transform Infrared Spectroscopy (FTIR).
Fourier transform infrared spectroscopy (FTIR) studies were
performed using a Spectrum 100 FTIR spectrometer
(PerkinElmer, USA), and spectra were collected in the range
of 4000−650 cm−1 with a total of 16 scans and a resolution of 2
cm−1, unless otherwise stated. Background scans were
performed in all experiments.
2.10. Determination of Drug Loading. λmax of CPM was
determined by scanning CPM at a concentration range of 5−50
μg/mL between 200 and 300 nm, with steps of 5 nm, using a
UV−vis spectrophotometer, SpectraMax (San Jose, CA, USA).
Data were collected using SoftMax Pro software. Standard
solutions of CPM with the concentration range of 5−50 μg/mL
were prepared in ethanol. A standard curve (R2 = 0.9988) of
CPM was plotted using absorbance data recorded using a
Jenway 6305 UV−vis spectrophotometer (Bibby Scientiﬁc,
Staﬀordshire, UK). Absorbance was recorded at 205 nm (λmax).
Drug loading was calculated by using the slope = 0.07525 and
intercept = 0.03447 of the standard curve.
2.11. Statistical Analysis. All experiments were conducted
in triplicate unless otherwise stated. All data were presented as
mean value ± standard deviation. Statistical signiﬁcance was
taken at p-value < 0.05.
2.12. E-Tongue Taste Assessment. 2.12.1. Measurement
Procedure. The TS-5000Z (Insent Inc., Atsugi-shi, Japan) was
equipped with four lipid membrane sensors and two
corresponding reference electrodes (New Food Innovation
Ltd., UK). Positively charged membrane sensors included C00,
responding to acidic bitterness, and AE1, responding to
astringency. Negatively charged membrane sensors included
AC0 and AN0, both responding to basic bitterness at diﬀerent
sensitivity and selectivity levels.
The reference solution was prepared by dissolving 30mmol/L
potassium chloride and 0.3 mmol/L tartaric acid in distilled
water. The negatively charged membrane washing solution was
prepared by diluting absolute ethanol to 30% v/v with distilled
water, followed by the addition of 100 mmol/L hydrochloric
acid. The positively charged membrane washing solution was
prepared by diluting absolute ethanol to 30% v/v and adding
100 mmol/L potassium chloride and 10 mmol/L potassium
hydroxide to the mixture. Tartaric acid, potassium chloride, and
potassium hydroxide were obtained from Sigma-Aldrich (UK).
Iso-alpha acid was obtained from Insent (Atsugi-shi, Japan).
Hydrochloric acid was obtained from Fisher Chemicals
(Loughborough, UK). All substances were used as received. A
sensor check was conducted routinely before each measurement
Table 1. Factors Investigated in the Electrospinning of E-
EPO Using a Deﬁnitive Screening Design
factor low medium high
applied voltage (kV) 10.00 17.50 25.00
ﬂow rate (mL/h) 0.50 1.25 2.00
gap distance (mm) 150 200 250
E-EPO concentration (% w/v) 25.00 35.00 45.00
water in solvent (% v/v) 0.00 10.00 20.00
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to ensure that the sensors were working within the correct
millivolt range.
Each measurement cycle consisted of measuring reference
potential (Vr) in reference solution, followed by the measure-
ment of electric potential (Vs) of the sample solution; Vs − Vr
represented the initial taste.28
The sensors were ﬁnally refreshed in alcohol solutions before
measurement of the next sample.
2.12.2. Sample Preparation. Taste extracted liquids were
used for biosensor assessment. The dose unit of CPM was set at
1 mg. For taste evaluation, 20 dose units (equivalent to 20 mg of
CPM) were added to 100 mL of 10 mmol potassium chloride
solution, as a supporting electrolyte, at 37 °C and gently stirred
for 1 min. This represented a concentration of one dose in 5 mL,
which was suitable for taste assessment as there was only slight
dilution of the sample. The mixture was then ﬁltered through
0.22 μm ﬁlters (Merck-Millipore, Cork, Ireland), removing any
suspended particles.
2.12.3. Data Analysis. All measurements were repeated four
times. The data from the ﬁrst run were discarded to allow for the
conditioning of sensors. In this study, a solution of 10 mmol
potassium chloride was used as a control sample, and the
corresponding sensor responses were subtracted from the sensor
responses of the samples. Hence, all data produced are a mean of
three measurements and represent relative sensor responses.
Multivariate principal component analysis (PCA) was per-
formed on the data collected. This aided visualization of the high
number of data points on a two-dimensional map. Diﬀerences
between samples were assessed by determining the Euclidean
distances, which were calculated from the cluster center.29 All
data analysis was carried out using OriginPro 9.4 (Origin Lab,
Massachusetts, USA).
3. RESULTS AND DISCUSSION
3.1. Chain Entanglement Concentration. Concentra-
tions of E-EPO ranging from 20 to 50% w/v were electrospun
and the solution viscosity was characterized to determine a chain
entanglement concentration as described by Kong and Ziegler.30
This is deﬁned as the intercept between the two ﬁtted lines
representing untangled and entangled regions, as shown in
Figure 2. The chain entanglement concentration represents the
point at which smooth ﬁbers start to form and is therefore
signiﬁcant for the viability of electrospinning;31,32 this was found
to be at 32.5% w/v for E-EPO.
To support the viscosity measurements, SEM visual
representation of the electrospun E-EPO ﬁbers is shown in
Figure 3.
Figure 3a−c shows the occurrence of electrospraying at 15
and 20% E-EPO. As the polymer concentration increases, a
transition between spraying and electrospinning occurs. Fiber
formation starts at 25% E-EPO; however, it was not until 30% E-
EPO that smooth ﬁbers were formed (Figure 3d). Figure 3e−h
also shows smooth ﬁbers with no bead-on-strings. Although
ﬁbers are smooth at this stage, it can be seen from Figure 4 that
as the polymer concentration increases, the ﬁber diameter also
increases, which can be attributed to the fact that more polymer
was dispensed through the needle. It can be observed that the
Figure 2. Instantaneous viscosity at a shear stress of 5 Pa as a function of
E-EPO concentration.
Figure 3. SEM images of electrospun E-EPO ﬁbers: (a) 15, (b) 20, (c)
25, (d) 30, (e) 35, (f) 40, (g) 45, and (h) 50% w/v. All ﬁbers were
processed at applied voltages of 10−20 kV, a ﬂow rate of 1 mL/h, a gap
distance of 200 mm, a temperature of 26 °C, and a RH of 32%.
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ﬁbers formed are ribbonlike, and this was likely to be due to the
rapid evaporation of the solvent causing the ﬁber to collapse and
appear ﬂat.33
3.2. DoE Deﬁnitive Screening Design. The DoE
deﬁnitive screening design aimed to screen the most inﬂuential
factors aﬀecting ﬁber diameter and beading, thus facilitating the
optimization of the electrospinning process. This type of DoE
requires only a small number of runs to identify most important
factors quickly and eﬃciently. Table 2 shows the parameters
investigated, the levels tested for each, and the associated results.
If a systematic approach was used to run experiments for all
combinations of the ﬁve chosen factors at three levels for each,
this would have resulted in 35 or 243 separate experiments. The
design allowed for screening with only 14 runs, investigating the
main eﬀects of the parameters on the outputs: diameter and
beading.
From Table 2, it can be seen that samples 7 and 12 were both
run at the same conditions, known as center points (CP) of the
design. It was noted that sample 12 yielded beaded ﬁbers, while
sample 7 was electrospun into smooth ﬁbers. It is well
documented that environmental conditions aﬀect electrospun
ﬁbers, and it is a factor that needs to be taken into consideration
with electrospinning.34
Figure 5 shows the statistical signiﬁcance level of each of the
parameters investigated on both outputs when modeled
together. P-value is expressed on the log scale; the vertical
dashed line represents the statistically signiﬁcant level of log(p-
value) = 0.05. Polymer concentration was found to be the only
statistically signiﬁcant factor. If increased, it reduced beading
defects, whereas if decreased, it reduced the ﬁber diameter.
3.2.1. Fiber Diameter. The eﬀect of adding water to ethanol
in the solvent mixture was not found to be a statistically
signiﬁcant factor for E-EPO ﬁber diameter reduction (p-value =
0.2572). Water increases the dielectric constant of the solvent
and can lead to a reduced diameter of the ﬁber because of
increased stretching of the ﬁbers, as in the case of sample 11,
where the addition of 20% v/v water to the solvent yielded a
mean ﬁber diameter of 2789 ± 677 nm. On the other hand,
sample 4 had no water in the solvent mixture, and it had a mean
ﬁber diameter of 4207± 78 nm.Water addition can also increase
the viscosity of a solution and therefore can lead to an increased
diameter, as is the case with sample 2 (20% v/v water), yielding a
diameter of 3078 ± 741 nm, as compared to sample 1 (10% v/v
water), which yielded a diameter of 2358 ± 782 nm.35
Figure 4. Mean ﬁber diameter vs concentration of E-EPO. The error
bars represent the ﬁber diameter distribution at each concentration.
Table 2. DoE Deﬁnitive Screening Design: Parameters Investigated and Findings
sample block
applied
voltage (kV)
ﬂow rate
(mL/h)
gap distance
(mm)
water
(% v/v)
E-EPO conc.
(% w/v) beadinga pH
conductivity
(μS/cm)
viscosity
(mPa s)
diameter
(nm)
1 1 25 2 150 10 45 0 8.4 6.20 ± 0.4 1650 ± 43 2358 ± 782
2 1 17.5 2 250 20 45 0 8.9 5.65 ± 0.6 2068 ± 47 3078 ± 741
3 1 25 1.25 150 20 25 105 8.7 9.57 ± 0.5 76 ± 6 259 ± 58
4 1 10 1.25 250 0 45 0 8.3 2.03 ± 0.2 444 ± 14 4207 ± 78
5 1 10 0.5 250 10 25 NF 8.6 6.38 ± 0.3 51 ± 6 N/A
6 1 17.5 0.5 150 0 25 60 8.7 3.24 ± 0.4 63 ± 2 483 ± 181
7 CP-1 17.5 1.25 200 10 35 0 8.9 5.01 ± 0.2 176 ± 17 1574 ± 535
8 2 25 2 250 0 25 145 8.9 3.24 ± 0.4 63 ± 2 416 ± 359
9 2 25 0.5 200 0 45 0 8.9 2.03 ± 0.2 444 ± 14 2557 ± 395
10 2 10 2 200 20 25 NF 9.2 9.57 ± 0.5 76 ± 6 N/A
11 2 10 0.5 150 20 45 0 9.2 5.65 ± 0.6 2068 ± 47 2789 ± 677
12 CP-2 17.5 1.25 200 10 35 65 8.7 5.01 ± 0.2 176 ± 17 436 ± 162
13 2 25 0.5 250 20 35 65 8.9 6.90 ± 0.2 133 ± 25 260 ± 68
14 2 10 2 150 0 35 NF 8.5 2.17 ± 0.1 143 ± 5 N/A
aApproximate number, counted in SEM ×5000 mag image. NF recorded when spraying occurred and no ﬁbers were formedthose data were
excluded from prediction.
Figure 5. Pareto chart showing the statistical signiﬁcance of the various
parameters in producing bead-free ﬁbers with a small diameter. The
vertical dashed line represents the signiﬁcance level of log p-value =
0.05.
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Similar to the addition of water, the applied voltage was not
found to be statistically signiﬁcant in reducing the diameter of E-
EPO ﬁbers (p-value = 0.2197). Nonetheless, as the applied
voltage increases, the electric ﬁeld is enhanced accelerating the
jet, and hence, its stretching gives rise to smaller ﬁbers. However,
although minor, an increase in applied voltage can also cause an
increase in polymer drawn, thereby increasing the ﬁber
diameter. Therefore, depending on conditions, it can lead to
either an increase or a decrease or it has no eﬀect at all on ﬁber
diameter. Although an increase in ﬂow rate was observed to
show an increase in ﬁber diameter, this was not found to be
statistically signiﬁcant (p-value = 0.8203). An increase in gap
distance increases the ﬂight jet time and elongates the polymer
jet stretching out and therefore can reduce the ﬁber diameter,
but it was also not found to be statistically signiﬁcant (p-value =
0.6413).
The screening design showed that out of those parameters
studied in the stated ranges, polymer concentration was the only
statistically signiﬁcant factor in reducing the ﬁber diameter (p-
value = 0.0076).
The ANOVA data show that the input parameters studied
explain the reduction in mean ﬁber diameter observed. The
error’s sum of squares is less than the model’s sum of squares,
and therefore, the variance in the ﬁber diameter is explained by
the statistically signiﬁcant eﬀect of the input parameters (p-value
= 0.0362) and not by pure chance or error. The sum of errors is
shown as the corrected total or C. total. The degrees of freedom
(DF) represent how many values in the calculation have the
freedom to vary, and they are equal to the number of
observations minus the number of parameters studied in the
model. The model’s DF is 6 because out of 14 runs, 2
observations were eliminated as no electrospinning occurred; 12
minus 6 parameters (applied voltage, ﬂow rate, gap distance,
solvent, polymer concentration, and block) equates to 6 DF.
The ANOVA data are shown in Table 3.
3.2.2. Beading. The eﬀect of water addition was not found to
be statistically signiﬁcant on beading (p-value = 0.2572). The
addition of water increased the conductivity of the solutions,
which reduced beading on some occasions; however, in other
instances, beading increased because water was not evaporating
by the time the ﬁbers deposited on the collector. An increase in
applied voltage can reduce beading by improving Taylor cone
stability through overcoming the surface tension and eventually
stopping dripping.36 This eﬀect was not statistically signiﬁcant
on the reduction of beading in E-EPO ﬁbers (p-value = 0.7778).
Flow rate can increase beading as it can lead to Taylor cone
instability and therefore interruption of the jet stream. This
however was not found to be statistically signiﬁcant on reducing
beading (p-value = 0.8203). An increase in gap distance can lead
to increased beading because of a weakened electric ﬁeld and
therefore reduced solvent evaporation.37 However, this eﬀect
was not found to be statistically signiﬁcant on the reduction of
beading (p-value = 0.6966). Similar to its eﬀect on ﬁber
diameter, polymer concentration was the only statistically
signiﬁcant parameter in reducing beading (p-value = 0.0042).
Figure 6 shows SEM images of sample 7 and sample 11 ﬁbers.
At 35% w/v E-EPO, smooth ﬁbers are formed. At 45% w/v E-
EPO, smooth ﬁbers are also generated; however, needle
clogging becomes very problematic at this high concentration.
Cleaning of the needle tip manually was repeated, which would
have resulted in discontinuation of a single continuous ﬁber.
This has therefore been identiﬁed as a rate-limiting factor, and E-
EPO was not recommended to be electrospun at concentrations
any higher than 35% w/v.
The ANOVA data show that the input parameters studied
explain the reduction in beading observed. The error’s sum of
squares is less than the model’s sum of squares, and therefore,
the variance in the beading recorded is explained by the
statistically signiﬁcant eﬀect of the input parameters (p-value =
0.0287) and not by pure chance or error. The ANOVA data are
shown in Table 4.
3.3. Optimization. Using standard least squares regression
analysis model, a predictive tool was used to predict ﬁber
diameter and beading number. To determine the reliability of
the predictive model, a summary of the ﬁt is shown in Figure 7.
The regression model for the reduction of ﬁber diameter data
had an R2 of 0.92, which means that 92% of the predicted
diameters are within the conﬁdence intervals of the actual
diameters recorded. Similarly, the predicted beading regression
analysis, R2 = 0.93, also had a very positive correlation with the
actual beading numbers recorded, showing that 93% of the
model predictions are within the conﬁdence intervals of the
actual beading data recorded. Both conﬁdence curves cross the
horizontal lines, which indicate that the predictions are
statistically signiﬁcant to the actual measurements.
3.3.1. Minimizing Beading. As well as screening key
parameters, the deﬁnitive screening design was used to predict
optimum conditions. For bead-free ﬁbers, these were predicted
to be 45% w/v E-EPO, 20% v/v water, ﬂow rate of 0.9 mL/h,
applied voltage of ∼21 kV, and gap distance of 150 mm, with an
R2 of 0.93, as shown in Figure 7. This was validated
experimentally, thereby lending weight to the predictive
approach (temperature: 19 °C, RH 32%) The ﬁbers had a
mean diameter of 4317 ± 1942 nm.
Table 3. ANOVA Data for Reduced Diameter
source DF sum of squares mean square F ratio
model 6 17 828 619 2 971 437 7.4530
error 4 1 594 765 398 691 prob > F
C. total 10 19 423 384 0.0362
Figure 6. Left: DoE sample 7, 35% w/v E-EPO, 10% v/v water in
solvent; process parameters: 17.5 kV, 1.25 mL/h, and 200 mm. Right:
DoE sample 11, 45% w/v E-EPO, 20% v/v water added in solvent;
process parameters: an applied voltage of 10 kV, a ﬂow rate of 0.5 mL/h,
and a gap distance of 150 mm.
Table 4. ANOVA Data for Reduced Beading
source DF sum of squares mean square F ratio
model 6 24573 4095 8.5
error 4 1926 481 prob > F
C. total 10 26 500 0.0287
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3.3.2. Minimizing Diameter. Minimizing ﬁber diameter was
most aﬀected by a decrease in polymer concentration (p-value =
0.008). The optimum parameters were predicted to be 28% w/v
E-EPO and 20% v/v water at a ﬂow rate of 0.5 mL/h, an applied
voltage of 25 kV, and a gap distance of 150mm to generate ﬁbers
with a mean diameter of 155 nm, R2 = 0.92. Experimental
validation produced nonbeaded ﬁbers with a mean diameter of
930 nm (±348), temperature 28 °C, and RH 36%.
3.3.3. Minimizing Beading and Diameter Together. When
both outcomes were modeled together, the prediction proﬁler
tool, shown in Figure 8, predicted that at 25 kV, 35% w/v E-
EPO, 0.5 mL/h ﬂow rate, a gap distance of 150 mm, and an
addition of 20% v/v water, ﬁbers with a mean diameter of 621
nm will be formed. They will also contain 37 beads per 3 mm2
(i.e., very low beading). When validated experimentally,
nonbeaded ﬁbers with an average diameter of 1904 nm
(±705) were formed; temperature: 28 °C, RH 36%.
An SEM image shows the ﬁbers produced and a histogram of
ﬁber diameter distribution in Figure 9.
3.4. Addition of CPM. CPM was initially electrospun with
E-EPO at ratios ranging from 1:2 to 1:6, CPM/E-EPO; it was
shown that ﬁber formation started to occur at ratios above 1:4.
Electrospinning does not occur below this drug load, and this is
likely due to the fact that the highly charged CPM molecules
repel and cause the jet to split into particles rather than to
deposit as the ﬁbrous material. CPM was then added using the
deﬁned optimized electrospinning condition ranges of E-EPO at
drug ratios of 1:6, 1:7, 1:8, 1:9, and 1:10. Input and output
parameters, namely, pH, ﬁber diameter, and drug-loading
measurements were recorded. The pH of E-EPO and CPM
solutions had a mean value of 7.49 ± 0.2. This is neutral and
therefore should not be irritating for the oral mucosa, which is an
important consideration because the ﬁbers are formulated for
oral drug delivery. Electrospinning was completed at temper-
atures of 21.8 ± 2.03 °C and RH of 34.5 ± 11%.
The drug loadings in Table 5 show good agreement with
theoretical entrapments; it is intended that the drug-loaded ﬁber
mats would eventually be administered to children in an age-
appropriate formulation such as a mini tablet or oral ﬁlm. If the
1:0 formulation were to be used, using the actual drug-loading
values, it can be seen than approximately 10 mg of ﬁber would
need to be ingested to deliver the clinical dose of 1 mg. CPM’s
dosage ranges from 1 mg twice a day for young infants to 1−4
mg up to 4 times a day in older children.38
As expected, in the presence of CPM, the average E-EPO ﬁber
diameter increases steadily as the polymer concentration was
increased.
The SEM images of drug-loaded ﬁbers at 1:6, 1:8, and 1:10
CPM/E-EPO are shown in Figure 10. It can be seen that as the
Figure 7. Summary of ﬁt predicting the diameter and number of beads
in electrospun E-EPO ﬁbers. Block line represents the linear ﬁt and
dashed outer lines represent the conﬁdence curve, while the horizontal
dashed line represents the hypothesized predicted outcomes at
optimum conditions.
Figure 8. Prediction tool showing the relationship between the input parameters and outcome. The x-axis represents input parameters and the y-axis
represents the outcomes predicted and the desirability. The desirability column shows negative sloped lines, indicating the desire to minimize beading
and ﬁber diameter. The dashed lines show the intersection between the values of the input and output parameters. The block lines show the
relationship between input parameters and the outputs.
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drug loading was reduced, smoother ﬁbers were formed, with a
smaller average diameter. The drug load therefore was
signiﬁcant on the viability of electrospinning. The poor
formation of ﬁbers at a high drug load was due to the increased
conductivity of the solution, which causes repulsion in the jet
stream and thereby impedes the formation of smooth ﬁbers.
It can be seen from the ﬁber diameter histograms that as the
drug amount added was decreased, the ﬁber diameter decreases
Figure 9. SEM image of electrospun 35% w/v E-EPO, DoE predicted parameters for bead-free ﬁbers in the nanorange: an applied voltage of 25 kV, a
ﬂow rate of 0.5 mL/h, and a gap distance of 150 mm. A histogram showing ﬁber diameter distribution of n = 100.
Table 5. Drug-Loading Values of Electrospun Fibers
CPM/E-EPO theoretical drug load (%) actual drug load (%)
1:6 14.3 15.4 ± 2.6
1:8 11.1 9.8 ± 0.3
1:10 9.1 9.3 ± 0.6
Figure 10. SEM images and histograms showing diameter distribution of 35% w/v E-EPO electrospun ﬁbers at an applied voltage of 15 kV, a ﬂow rate
of 1 mL/h, and a gap distance of 175 mm. Top1:6 CPM/E-EPO. Middle1:8 CPM/E-EPO. Bottom1:10 CPM/E-EPO.
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steadily. Smoother ﬁbers were also formed as the drug loading
reduced; this was probably due to the fact that there are less
charged species, and therefore, repulsive forces are reduced,
allowing for better ﬁber formation. As the drug loading was
increased, the conductivity increases, and in the presence of
water, this is even higher. Because drug-loaded solutions are
being highly conductive, multiple jets form at the nozzle, and
this may explain the large range of ﬁber diameter distribution
seen.
3.5. Multifactorial Interactions. The main eﬀects of
polymer concentration, water addition, applied voltage, ﬂow
rate, gap distance, and the addition of a drug have so far been
discussed in the electrospinning of E-EPO. The DoE completed
for manufacturing optimization of E-EPO aimed at screening for
the most inﬂuential factors. Multifactorial interactions are useful
to gain a deeper understanding of the electrospinning process.
Forty-two experiments of drug-loaded E-EPO were completed.
The eﬀect of each parameter andmultifactorial interactions were
investigated on reducing the ﬁber diameter. Beading was not
explored at this stage, as it was completely eliminated by
electrospinning the drug-loaded solutions above the critical
entanglement concentration of E-EPO.
Figure 11 shows that both polymer concentration and ﬂow
rate had statistically signiﬁcant eﬀects on reducing the ﬁber
diameter of drug-loaded E-EPO ﬁbers. It is to be noted that the
ﬂow rate’s signiﬁcant eﬀect was likely not due to the drug
addition in itself versus E-EPO on its own but due to the higher
number of experiments run and therefore increased power.
The interaction between the ﬂow rate and polymer
concentration also played a role in aﬀecting the ﬁber diameter
and was found to be statistically signiﬁcant. The variation of one
of those parameters can inﬂuence the eﬀect of the other on the
outcome. At a low polymer concentration, the ﬁber diameter is
decreased; however, a suﬃcient ﬂow rate is needed to ensure the
feasibility of the electrospinning process and the formation of a
continuous Taylor cone and therefore the production of ﬁbers.
This interaction is in line with the ﬁndings of Ruiter et al.21
3.6. Thermogravimetric Analysis. The degradation
proﬁles for pure E-EPO and CPM were analyzed using TGA.
Minimal solvent loss (<1% of weight) was observed in the
temperature range for water evaporation. Data observed from
the TGA measurements were used to determine temperature
ranges for DSC measurement. Similar to the raw materials,
minimal solvent loss (<1% of weight) was observed for both the
placebo and active ﬁbers around ethanol’s, 78 °C, or water’s
boiling point, 100 °C.39
3.7. X-ray Diﬀraction. XRD patterns in Figure 12a show
distinct peaks of CPM, indicating a crystalline state, whereas E-
EPO shows a halo that indicates an amorphous state. The
placebo ﬁber’s diﬀraction pattern shows a halo indicative of the
amorphous state; however, it appears very ﬂat. This is probably
due to the low sensitivity slow scanning rate used at 3°/min with
a step size of 0.02°. To conﬁrm that this was the cause, drug-
loaded ﬁbers and the raw ingredients’ physical mixture were
recorded over the ranges of 3°−40° at a scan rate of 5°/min with
a step size of 0.005°, improving the sensitivity of the diﬀraction
pattern recorded. The diﬀraction pattern shown in Figure 12b
shows more distinct shapes at the same intensity as that of CPM
and E-EPO’s physical mixture. It can be seen that the drug-
loaded diﬀraction patterns appear as halos similar to the placebo
ﬁber and unformulated E-EPO indicative of amorphous solid
dispersion formation. This shows that CPM changes to the
amorphous state following electrospinning. The rapid evapo-
ration of solutions through electrospinning, followed by quick
solid dispersion, explains the formation of amorphous single
phase systems.
3.8. Fourier Transform Infrared Spectroscopy. In Figure
13, the peak observed in E-EPO at 1210 cm−1 is characteristic of
Figure 11. Pareto chart showing the statistical signiﬁcance of the
various parameters in producing drug-loaded E-EPO ﬁbers with a small
diameter. The vertical dashed line represents the signiﬁcance level of
log p-value = 0.05.
Figure 12. (a) XRD pattern of pure E-EPO, pure CPM, and placebo
35% w/v E-EPO ﬁber. (b) XRD pattern of E-EPO and CPM physical
mixture, 35% w/v E-EPO + 1:6 CPM/E-EPO ﬁbers and 35% w/v E-
EPO + 1:8 CPM/E-EPO ﬁbers.
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the C−Obond and that at 1720 cm−1 is characteristic of the C
O bond and is present in the physical mixture and the
electrospun ﬁbers. Both the placebo ﬁber and the drug-loaded
ﬁber’s spectra are almost identical, indicating that no bonds were
formed between the polymer E-EPO and the drug CPM, further
validating the XRD data that an amorphous solid dispersion was
formed.
3.9. Diﬀerential Scanning Calorimetry. MTDSC meas-
urements were carried out to determine the melting point (Tm)
of CPM and the glass transition (Tg) of E-EPO. Midpoint values
were recorded. E-EPO’s Tg was recorded as 50.9 °C, consistent
with literature ﬁndings.40 CPM’s Tm was recorded as 133.24 °C,
in close agreement with the reported literature value of 130−135
°C.41
When the physical mixture of CPM and E-EPO was tested,
both an endothermic melting trough at 133.51 ± 0.43 °C and a
Tg shift at 49.7 ± 0.89 °C were observed, indicating that both
compounds were detected. The intensity of the melting peak
was less in the physical mixture than in pure CPM, which could
be explained by the dilution eﬀect of the polymer.42
Electrospun ﬁbers were then tested. An E-EPO placebo ﬁber
was tested, and an endothermic shift was observed at 50.74 ±
0.66 °C, indicating a Tg shift. Drug-loaded ﬁbers did not display
a melting peak which indicates the conversion of crystalline
CPM to the amorphous state. Representative DSC results are
shown in Figure 14.
3.10. E-Tongue.One of themain limitations of the E-tongue
is that it can only detect drugs ionizable in the medium used for
the measurement.25 The ﬁrst step was to therefore determine if
the drug in question, CPM, was detectable by the E-tongue’s
taste sensors. It was conﬁrmed that the E-tongue can detect
CPM as a bitter drug. All sensors used showed a concentration-
dependent response to CPM as shown in Figure 15.
Taste sensor output was obtained bymeasuring a diﬀerence in
electric potential between the taste sensor and the reference
electrode. Table 6 shows the data for Euclidean distances
between pure CPM and pure E-EPO, physical mixtures, placebo
ﬁber, and 1:8 and 1:6 drug-loaded ﬁbers. As anticipated, pure E-
EPO and placebo ﬁbers tested had the largest Euclidean
distance, an arbitrary distance from the pure bitter drug; the
higher the distance, the lower the bitterness of the sample.43
This was followed by the drug-loaded ﬁbers and ﬁnally by the
physical mixture. Drug-loaded ﬁbers had a larger distance than
the physical mixture, indicating better taste-masking.
Figure 16 shows a PCA biplot illustrating the distances from
pure CPM. The dataset is projected onto a space relative to their
distance from the two main principal components, which
represent the axes of the map and correspond to the variance in
the data.
PCA showed that the basic bitterness sensors AC0 and AN0
were responsible for principal component 1 (77.3% of variance).
C00, the acidic bitterness sensor, was responsible for the second
Figure 13. FTIR spectra of unformulated pure CPM, E-EPO, their
physical mixture, 35% w/v E-EPO placebo ﬁber, and 1:6 and 1:8 CPM/
E-EPO drug-loaded ﬁbers.
Figure 14. DSC thermogram of pure CPM, physical mixture, pure E-
EPO, 35%E-EPO placebo ﬁber, 35%w/v E-EPO+ 1:6 CPM ﬁbers, and
35% w/v E-EPO + 1:8 CPM/E-EPO ﬁbers. Exo up.
Figure 15. Analysis of sensor responses to various concentrations of
CPM: AC0basic bitterness; AN0basic bitterness; C00acidic
bitterness; AE1astringency.
Table 6. Euclidean Distances for Pure E-EPO, Physical
Mixture, Placebo Fiber, and Drug-Loaded Fibers from Pure
CPM
sample Euclidean distance
physical mixture 3
active ﬁber 35% 1:6 CPM 3
active ﬁber 35% 1:8 CPM 5
placebo ﬁber 30% 9
pure E-EPO 11
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principal component (22.4% of variance). This has a cumulative
variance of 99.7%, which indicated that the change in data
observed can be explained by the true change in taste as detected
by the bitterness sensors. The upper right quadrant in the biplot
shows pure CPM located in the direction of the AN0 and AC0
vectors, indicating its basic bitter taste. Pure E-EPO seems to
elicit an acidic bitter response relative to the other samples;
when formulated by electrospinning, the placebo ﬁber’s C00, or
acidic bitterness response, was decreased compared to pure E-
EPO. The physical mixture and drug-loaded ﬁbers are located
neither in the basic bitterness nor in the acidic bitterness
quadrants. This indicates that both the addition of the taste-
masking polymer E-EPO and the process of electrospinning
reduce the bitterness sensor response, relative to the other
samples tested, concluding that the technique is capable of
encapsulating bitter drugs.
4. CONCLUSIONS
To conclude, we have found using the electronic tasting system
that electrospinning is a suitable taste-masking technology for
the formulation of bitter pharmaceuticals. Although electro-
spinning is a simple and low-cost technique, it is aﬀected by a
number of parameters, and if not controlled properly, the
outcomes can vary signiﬁcantly. A DoE approach helped to
accelerate the optimization process of electrospinning the E-
EPO, saving time and resources.
The study has not only identiﬁed parameters for producing E-
EPO ﬁbers but has also developed an approach for the rational
choice of electrospinning conditions, guiding the electro-
spinning of drug-loaded E-EPO ﬁbers. Adding CPM to E-
EPO changed both the conductivity and viscosity of the
solutions and therefore yielded ﬁbers with a diﬀerent
morphology. It was found that 35% w/v E-EPO ﬁbers that
have drug loads of 1:6 or higher yielded reproducible smooth
nonbeaded ﬁbers. Through solid-state characterization and
thermal analysis of the ﬁbers, it was shown that CPM is
amorphously dispersed in the polymeric carrier E-EPO.
While maintaining the beneﬁts of nanosizing a formulation,
electrospinning is a promising taste-masking technology that if
optimized eﬃciently through QbD principles can be utilized to
formulate age-appropriate dosage forms. Using the results from
this study, the drug-loaded ﬁbers would be further formulated
into an easy to swallow age-appropriate dosage form.
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